STAAR Surgical (NASDAQ:STAA) Receives $42.00 Consensus Target Price from Analysts
Shares of STAAR Surgical (NASDAQ:STAA) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $42.00.
Several research firms recently issued reports on STAA. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Zacks Investment Research lowered shares of Farmland Partners from a “hold” rating to a “sell” rating in a research note on Friday, July 12th. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Finally, Canaccord Genuity reduced their price objective on shares of Jamieson Wellness from C$23.00 to C$20.00 in a research note on Monday, May 6th.
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction that occurred on Friday, May 3rd. The stock was acquired at an average price of $22.23 per share, with a total value of $2,223,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.
Shares of NASDAQ:STAA traded down $0.56 during trading on Thursday, reaching $30.30. 650,700 shares of the company traded hands, compared to its average volume of 430,513. The company has a fifty day simple moving average of $29.62. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 108.21 and a beta of 2.32. STAAR Surgical has a 1-year low of $21.70 and a 1-year high of $54.00. The company has a current ratio of 5.41, a quick ratio of 4.83 and a debt-to-equity ratio of 0.04.
STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.06. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. The business had revenue of $32.58 million during the quarter, compared to analyst estimates of $32.40 million. During the same quarter in the previous year, the business earned $0.01 EPS. As a group, research analysts anticipate that STAAR Surgical will post 0.33 EPS for the current fiscal year.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Further Reading: What are the disadvantages of after-hours trading?
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.